Merck Annual Report 2007 - Sitemap (optimized for printing)

Merck 2007 at a glance
- Achievements of 2007
- Development 2003-2007
- Business sectors
- Financial calendar
Letter from Karl-Ludwig Kley
Corporate governance and bodies
- Corporate governance
  - Merck KGaA
  - Compensation and ownership of shares
- Report of the Supervisory Board
- Executive Board
  - Karl-Ludwig Kley
  - Michael Becker
  - Bernd Reckmann
  - Elmar Schnee
  - Walter W. Zywottek
- Supervisory Board
- Board of Partners of E. Merck OHG
Merck shares
- Share price development and influencing factors
- Share data
- Shareholder structure
- Information on capital and shares
Management Report
- Sales development
  - Business sectors
  - Regions
- Financial position and results of operations
  - Operating result
  - Earnings contributions
  - Financial result
  - Profit after tax
  - Dividend proposal
  - Free cash flow
  - Research and development
  - Capital spending
  - Total assets
  - Net debt
  - Value added
- Responsibility
  - Employees
  - Social Charter
  - Community
  - Environment
- Risk report
  - Business-related risks
  - Financial risks
  - Accounting risks
  - Legal risks
  - Other risks
- Report on expected developments
  - Merck
  - Pharmaceuticals
  - Chemicals
- Subsequent events
Management Report: Divisions
- In focus
  - Effective therapies
  - Strong presence in the US
  - Debut in Japan
  - Leadership in LCD
  - Detecting bacteria
  - A sunny future
- Merck Serono
  - Business development
  - Regions
  - Therapeutic areas
  - Markets
    - Oncology
    - Neurodegenerative Diseases
    - Fertility
    - Endocrinology
    - CardioMetabolic Care
    - Dermatology
  - Research and development
    - Overview compounds
    - Oncology
    - Neurodegenerative Diseases
    - Fertility
    - Autoimmune and inflammatory diseases
    - Endocrinology
- Consumer Health Care
  - Business development
  - Regions
  - Brands
- Liquid Crystals
  - Business development
  - Research and development
  - Trend toward LCD TVs
- Performance & Life Science Chemicals Profile
  - Business development
  - Regions
  - Laboratory Business
    - Profile
    - Business development
  - Life Science Solutions
    - Profile
    - Business development
  - Pigments
    - Profile
    - Business development
- Corporate and Other
- Generics
Financial Statements
- Income Statement
- Balance Sheet
- Segment Reporting
  - Business sectors
  - Regions
- Cash Flow Statement
- Free Cashflow
- Income and Expense
- Changes in Net Equity
Notes
- Reporting structure
- Acquisitions
- Disposals/Discontinued operations
- Accounting policies
- Notes to the income statement
  - Sales
  - Royalty income
  - Cost of sales
  - Marketing and selling expenses
  - Administration expenses
  - Other operating income and expenses
  - Research and development
  - Amortization of intangible assets
  - Investment result
  - Exceptional items
  - Financial result
  - Income tax
  - Profit after tax from discontinued operations
  - Minority interest
  - Earnings per share
- Notes to the balance sheet
  - Cash and cash equivalents
  - Marketable securities
  - Trade accounts receivable
  - Inventories
  - Other assets
  - Tax receivables
  - Assets/ liabilities held for sale
  - Intangible assets
  - Property, plant and equipment
  - Non-current financial assets
  - Financial liabilities
  - Trade accounts payable
  - Other liabilities
  - Tax liabilities
  - Provisions
  - Provisions for pensions
  - Net equity
- Notes to the segment reporting
- Notes to the cash flow statement
  - Net cash flows from operating activities
  - Net cash flows from investing activities
  - Net cash flows from financing activities
  - Cash and cash equivalents
  - Free cash flow
- Other disclosures
  - Derivative financial instruments
  - Management of financial risks
  - Other disclosures on financial instruments
  - Contingent liabilities
  - Other financial obligations
  - Personnel expenses
  - Material costs
  - Auditors' fees
  - Corporate Governance
  - Companies opting for exemption
  - Related-party disclosures
- Auditor's Report